ChromaDex Co. (NASDAQ:CDXC – Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.06 and traded as high as $3.36. ChromaDex shares last traded at $3.32, with a volume of 374,577 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a research report on Friday, August 9th. Roth Mkm reiterated a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a research report on Wednesday, June 12th.
Get Our Latest Research Report on CDXC
ChromaDex Stock Performance
Insider Transactions at ChromaDex
In related news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 9.64% of the stock is owned by corporate insiders.
Institutional Trading of ChromaDex
Several hedge funds have recently added to or reduced their stakes in CDXC. Miracle Mile Advisors LLC acquired a new stake in ChromaDex during the 2nd quarter worth $27,000. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex in the 2nd quarter valued at about $31,000. Merriman Wealth Management LLC acquired a new stake in shares of ChromaDex in the 2nd quarter valued at about $32,000. Lazard Asset Management LLC acquired a new stake in shares of ChromaDex in the 1st quarter valued at about $43,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex in the 1st quarter valued at about $54,000. Institutional investors and hedge funds own 15.41% of the company’s stock.
ChromaDex Company Profile
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Further Reading
- Five stocks we like better than ChromaDex
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Where Do I Find 52-Week Highs and Lows?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.